Difluprednate for inflammatory eye disorders

Drugs of Today

Volumn 47, Issue 5, 2011, Pages 327-333

  Mulki, L ^a   Foster, C Stephen ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; DIFLUPREDNATE; PREDNISOLONE ACETATE;

DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; HUMAN; INTRAOCULAR HYPERTENSION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UVEITIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENDOPHTHALMITIS; FLUPREDNISOLONE; HUMANS;

EID: 80052782126     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.5.1590791     Document Type: Review

References (21)

1. Nussenblatt, R.B. The natural history of uveitis. Int Ophthalmol 1990, 14(5-6): 303-8.
2. Tran, V.T., Auer, C., Guex-Crosier, Y., Pittet, N., Herbort, C.P. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 1994, 18(5): 293-8.
3. Henderly, D.E., Genstler, A.J., Smith, R.E., Rao, N.A. Changing patterns of uveitis. Am J Ophthalmol 1987, 103(2): 131-6.
4. Korenfeld, M. Difluprednate: Changing the landscape of ocular pharmacology. Expert Rev Ophthamol 2008, 3(6): 619-25.
5. Bikowski, J., Pillai, R., Shroot, B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 2006, 5(2): 125-30.
6. Tajika, T., Isowaki, A., Sakaki, H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther 2011, 27(1): 43-9.
7. Tajika, T., Waki, M., Tsuzuki, M., Kida, T., Sakaki, H. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptorbinding bioassay. J Ocul Pharmacol Ther 2011, 27(1): 29-34.
8. Davies, N.M. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000, 27(7): 558-62.
9. Tamilvanan, S. Oil-in-water lipid emulsions: Implications for parenteral and ocular delivering systems. Prog Lipid Res 2004, 43(6): 489-533.
10. Tamilvanan, S., Benita, S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm 2004, 58(2): 357-68.
11. Yamaguchi, M., Yasueda, S., Isowaki, A., Yamamoto, M., Kimura, M., Inada, K., Ohtori, A. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm 2005, 301(1-2): 121-8.
12. Stringer, W., Bryant, R. Dose uniformity of topical corticosteroid preparations: Difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol 2010, 4: 1119-24.
13. Yasueda, S., Kimura, M., Ohtori, A., Kakehi, K. Analysis of an anti-inflammatory steroidal drug, difluprednate, in aqueous humor by combination of semi-micro HPLC and column switching method. J Pharm Biomed Anal 2003, 30(6): 1735-42.
14. Okumura, A., Tsuzuki, M., Wada, T., Kida, T., Tajika, T., Sakaki, H., Ohtori, A. Efficacy of difluprednate ophthalmic emulsion in preclinical studies of uveitis. Invest Ophthalmol Vis Sci [Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 6-10, Fort Lauderdale) 2007] 2007, 48: Abst 2652-B742.
15. Kida, T., Takahashi, H., Tsuzuki, M., Tajika, T., Sakaki, H., Ohtori, A. Difluprednate emulsion inhibits postoperative inflammation in rabbit paracentesis model. Invest Ophthalmol Vis Sci [Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 6-10, Fort Lauderdale) 2007] 2007, 48: Abst 2655-B-745.
16. Foster, C.S., Davanzo, R., Flynn, T.E., McLeod, K., Vogel, R., Crockett, R.S. Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther 2010, 26(5): 475-83.
17. Korenfeld, M.S., Silverstein, S.M., Cooke, D.L., Vogel, R., Crockett, R.S. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg 2009, 35(1): 26-34.
18. Smith, S., Lorenz, D., Peace, J., McLeod, K., Crockett, R., Vogel, R. Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol 2010, 4: 983-91.
19. Donnenfeld, E.D., Holland, E.J., Solomon, K.D. The effect of pre- and postoperative difluprednate and prednisolone acetate on visual acuity and corneal pachymetry in cataract surgery. Annu Meet Am Acad Ophthalmol (Oct 16-19, Chicago) 2010, Poster 282.
20. Sakaki, H., Nemoto, S., Kida, T., Tajika, T., Ohtori, A. Preclinical toxicity of difluprednate emulsion. Invest Ophthalmol Vis Sci [Annu Meet Assoc Res Vision Ophthalmol (ARVO) (May 6-10, Fort Lauderdale) 2007] 2007, 48: Abst 2653-B743.
21. Nakano, S., Yamamoto, T., Kirii, E., Abe, S., Yamashita, H. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2010, 248(6): 805-10.